When cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman's pelvis (the area below your stomach and in between your hip bones). The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of your uterus, called the endometrium.
When uterine cancer is found early, treatment is most effective. The most common sign of uterine cancer is bleeding that is not normal for you because of when it happens or how heavy it is. This could mean bleeding, even a little bit, after you have gone through menopause; periods that are longer than seven days; bleeding between periods; or any other bleeding that is longer or heavier than is normal for you.
Other symptoms, such as pain or pressure in your pelvis, also may occur if you have uterine cancer. If you have any of these symptoms, talk to your doctor, nurse, or other health care professional right away. They may be caused by something other than cancer, but the only way to know is to see your health care professional.
When Linda Muller was diagnosed with serous cell endometrial cancer in 2016, she and her husband George turned to the all-female gynecologic oncology team at John Theurer Cancer Center at Hackensack University Medical Center for her care -; a decision that the couple credits with Linda's complete recovery and continued good health seven years later.
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.
The American Cancer Society has recently published the statistics of cancer incidence and mortality for 2023 in CA: A Cancer Journal for Clinicians.
Overall cancer death rates continued to decline among men, women, children, and adolescents and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer incidence, or new cases of cancer, remained stable for men and children but increased for women and adolescents and young adults.
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
What do pandemic preparedness, mental health care services, and over-the-counter hearing aids have in common? They are all things President Joe Biden touted on the campaign trail this week as he tries to maintain Democrats' majorities in Congress in the midterm elections Nov. 8.
A new study in the Journal of the National Cancer Institute aimed to analyze the association of hair product use with age-specific uterine cancer in a large, ethnically, and racially diverse population in the United States.
Women who used chemical hair straightening products were at higher risk for uterine cancer compared to women who did not report using these products, according to a new study from the National Institutes of Health.
The HSD3B1 gene could hold clues for predicting and treating endometrial cancer, according to a novel finding from the Cleveland Clinic's Lerner Research Institute.
Cancer patients are at a greater risk for developing diabetes, according to a new study by the Steno Diabetes Center Copenhagen, Rigshospitalet, and the University of Copenhagen.
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, a large epidemiologic study has found.
In April 2021, during the Leaders Summit on Climate, President Biden announced his goal to drastically reduce the United States' greenhouse gas emissions by 2030.
Deaths from uterine cancer are rising in the United States, and are highest among non-Hispanic Black women, according to a new study led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health.
A recently published paper in the journal Molecular Cancer by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Genetics Chairman at the University of Barcelona, shows that transfer RNAs for certain amino acids are altered at the epigenetic level in some types of cancer, expressing it in an exaggerated manner in some cases and being deficient in others.
No single gene causes uterine cancer, the fourth most common cancer among women, which is on the rise in the U.S.
Tammy Kaminski can still recall the taste of benzene, a carcinogenic byproduct of burning jet fuel. For nine months after the 9/11 attacks, she volunteered for eight hours every Saturday at St. Paul's Chapel, just around the corner from ground zero in New York City.
A team of scientists led by the University of Michigan Health Rogel Cancer Center has found that a class of U.S. Food and Drug Administration-approved drugs can effectively stop a highly aggressive type of uterine cancer in its tracks, paving a quick path toward new treatment strategies for a deadly cancer with limited therapeutic options.
New research being presented at The European Congress on Obesity (ECO) held online this year, suggests that a measure of body shape should be used alongside body mass index (BMI) to help determine the risk of obesity-related cancers.
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.